Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humoral immune response after hospital-wide COVID-19 vaccination
2021-006832-24Phase 4Completed
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Ziekenhuis Oost-Limburg. Primary endpoint: SARS-CoV-2 S-specific binding antibody titres. Started Dec 2021; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006832-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006832-24.